Overview of Product development partnerships

Evotec's clinical programmes are almost exclusively developed in partnerships with pharmaceutical companies.

Partner	Indication		Status	Next milestone
Teva/Andromeda	Type 1 Diabetes	Diapep277, synthetic peptide modulator	Second Phase III recruitment closed	Final Phase III data
Roche	Alzheimer's Disease	MAO-B inhibitor	Phase II recruiting	Completion of Phase II, Phase III start
JingXin	Insomnia	EVT201, Gaba_A	Phase II	Phase IIb start
Conba Pharmaceutical Co., Ltd.	Inflammation	EVT401	Phase I/II	Phase II start
Janssen Pharmaceuticals	Treatment resistant depression	EVT100 series	Phase I/II	Confirmation of pre-clinical study/Phase II start
Pfizer	Pain	TRPV1 antagonist	Pre-clinical	Phase I start
Boehringer Ingelheim	Type 2 Diabetes	Insulin Sensitizer	Research	Pre-clinical
Janssen (CureBeta)	Type 1 and 2 Diabetes		Research	Pre-clinical
MedImmune/AstraZeneca	Type 1 and 2 Diabetes	EVT770	Research	Pre-clinical